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PURPOSE. To investigate the role of two deep-intronic ABCA4 variants, that showed a mild
splice defect in vitro and can occur on the same allele as the low penetrant c.5603A>T, in
Stargardt disease (STGD1).
METHODS. Ophthalmic data were assessed of 18 STGD1 patients who harbored c.769-784C>T
or c.4253þ43G>A in combination with a severe ABCA4 variant. Subjects carrying c.[769-
784C>T; 5603A>T] were clinically compared with a STGD1 cohort previously published
carrying c.5603A>T noncomplex. We calculated the penetrances of the intronic variants
using ABCA4 allele frequency data of the general population and investigated the effect of
c.769-784C>T on splicing in photoreceptor progenitor cells (PPCs).
RESULTS. Mostly, late-onset, foveal-sparing STGD1 was observed among subjects harboring
c.769-784C>T or c.4253þ43G>A (median age of onset, 54.5 and 52.0 years, respectively).
However, ages of onset, phenotypes in fundo, and visual acuity courses varied widely. No
significant clinical differences were observed between the c.[769-784C>T; 5603A>T] cohort
and the c.4253þ43G>A or the c.5603A>T cohort. The penetrances of c.769-784C>T
(20.5%–39.6%) and c.4253þ43G>A (35.8%–43.1%) were reduced, when not considering the
effect of yet unidentified or known factors in cis, such as c.5603A>T (identified in 7/7
probands with c.769-784C>T; 1/8 probands with c.4253þ43G>A). Variant c.769-784C>T
resulted in a pseudo-exon insertion in 15% of the total mRNA (i.e., ~30% of the c.769-784C>T
allele alone).
CONCLUSIONS. Two mild intronic ABCA4 variants could further explain missing heritability in
late-onset STGD1, distinguishing it from AMD. The observed clinical variability and calculated
reduced penetrance urge research into modifiers within and outside of the ABCA4 gene.
Keywords: Stargardt disease, ABCA4, disease expression, penetrance, differential diagnosis
Stargardt disease (STGD1 [Mendelian Inheritance in Man:248200]) is typically characterized by rapid visual acuity
(VA) decline in childhood or early adulthood, and by yellow-
white pisciform flecks throughout the posterior pole and
macular atrophy on fundoscopy.1,2 We previously described a
cohort of patients with late-onset STGD1, which was charac-
terized by slowly progressive sharply demarcated retinal
pigment epithelium (RPE) atrophy in a foveal-sparing pat-
tern.3–5 However, the diagnosis of late-onset STGD1 remained
questionable due to unidentified disease-causing ABCA4 alleles,
and phenotypic overlap with other macular diseases, the most
frequent of which is AMD.6
Recently, a large part of the missing heritability of late-onset
STGD1 was elucidated by the frequent ABCA4 coding variant
c.5603A>T (p.Asn1868Ile), which was found to cause STGD1
only when present in combination with a deleterious muta-
tion.7 Interestingly, this mild variant was associated with an
exceptional clinical variability.8 Moreover, this variant clearly
showed reduced penetrance in the Dutch population (~5%),
that is, the vast majority of individuals carrying c.5603A>T in
trans with (i.e., positioned on the other allele as) a severe
variant do not manifest STGD1.8–10 Reduced penetrance has
rarely been reported in autosomal-recessive retinal diseas-
es.11–13 Occurrence of this phenomenon has major implica-
tions for genetic counseling and future directions for research
into modifying factors, which could result in targets for
therapeutics.
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Very recently, we identified eight deep-intronic variants
among 67% of genetically unsolved STGD1 patients.14 The two
most frequently identified variants, c.769-784C>T and
c.4253þ43G>A, only showed a partial splice defect in vitro.
Variant c.769-784C>T strengthened a cryptic splice site at a
noncanonical nucleotide position resulting in pseudo-exon
inclusion. As this c.769-784C>T variant was consistently found
in cis with (i.e., positioned on the same allele as) the mild
c.5603A>T variant, its causal role could not be fully established
yet. Variant c.4253þ43G>A disrupted predicted splice silenc-
ers and created an exonic splicing enhancer leading to partial
skipping of exon 28. Like c.5603A>T, variant c.4253þ43G>A
was associated with late-onset STGD1 and found to be
phenotypically expressed only when in trans with a severe
variant.15
In this study, we investigate the phenotypic characteristics
associated with deep-intronic ABCA4 variants c.769-784C>T
and c.4253þ43G>A, and clinically compared these patients
with our previously described patient cohort carrying
c.5603A>T without variants in cis. Furthermore, we aim to
strengthen the observation that c.769-784C>T has an effect on
splicing, and to assess the penetrance of both intronic variants.
This information is paramount for the differential diagnostics of
late-onset STGD1 and to discern this disease from AMD.
METHODS
Subjects
Participants originated from the population of STGD1 patients
in ophthalmic centers in The Netherlands participating in the
RD5000 study group.16 Fifteen genetically unexplained pro-
bands and three affected siblings in whom the c.768-784C>T
variant or the c.4253þ43G>A variant was found as the second
allele, after HaloPlex-based (Agilent, Santa Clara, CA, USA)
sequencing and segregation analysis by Sangermano et al.,14
were identified. All records were reviewed retrospectively.
Additionally, skin biopsies were collected from a STGD1
patient harboring c.769-784C>T and a control individual, and
splice assays were performed in photoreceptor progenitor cells
(PPCs). Ultimately, we performed penetrance calculations
employing ABCA4 allele frequency data of one European and
two Dutch population databases.
All procedures were approved by the Medical Ethics
Committee of Erasmus Medical Center (MEC-2010-359).
Informed consent was obtained after explanation of the study,
and the study adhered to the tenets of the Declaration of
Helsinki.
Clinical Evaluation
Clinical data collected from medical records included age of
onset and initial symptoms, age at diagnosis, best-corrected VA,
findings on ophthalmoscopy, retinal imaging, and full-field (ff)
ERG. We examined available fundus photography, fundus
autofluorescence (FAF) imaging (using a confocal scanning
laser ophthalmoscope; Spectralis; Heidelberg Engineering,
Heidelberg, Germany), spectral domain–optical coherence
tomography (OCT; Spectralis or Cirrus; Carl Zeiss Meditec,
Inc., Dublin, CA, USA), and ffERG acquired according to the
International Society for Clinical Electrophysiology of Vision
standards.17 We assessed the presence of foveal sparing, which
we defined as RPE atrophy encircling a structurally and
functionally (VA ‡20/200 Snellen) preserved fovea by 1808
or more, by evaluation of FAF and/or OCT.4 The previously
described definition ‘definitely decreased autofluorescence’
was used in the assessment of FAF.18
Age of onset was defined as the age at which the patient
first experienced visual complaints. In asymptomatic subjects
or in case age at onset was not reported, we used the age at
which decrease in VA was first documented or the age at which
macular abnormalities were first diagnosed. Age of onset was
compared across patient groups with different ABCA4
genotypes, using Mann-Whitney U tests for independent
samples. A P value < 0.05 was considered statistically
significant.
We performed Kaplan-Meier survival analysis to determine
the median survival time to develop severe visual impairment,
defined as a VA of less than 20/200 Snellen (decimal, 0.10) in
accordance with the International Classification of Diseases,
11th revision.19 Patients were censored if the time interval
between the first measurement of severe visual impairment
and the prior visit was more than 5 years, and patients were
excluded if VA was available at only one time point and already
was less than 20/200 Snellen. Additionally, we investigated
whether c.769-784C>T has an additive effect on disease
severity compared with the c.5603A>T variant alone by
including age at onset and VA data of a previously described
cohort of STGD1 patients carrying the noncomplex
c.5603A>T variant.8
Assessment of RNA Splice Defects in Photoreceptor
Progenitor Cells
To determine whether deep-intronic variant c.769-784C>T
results in aberrant splicing of ABCA4 pre-mRNA, fibroblasts of
a patient and a control were reprogrammed into induced
pluripotent stem cells and differentiated into PPCs as
previously described.20 All differentiations were performed in
duplicate. RT-PCR was performed using ABCA4 exonic primers
located in ABCA4 exon 6 and 8. Gel resolution, excision, and
purification of the bands of RT-PCR products, and Sanger
sequencing were performed as described elsewhere.20 Details
of RT-PCR primers are given in Supplementary Table S1.
To determine the fraction of correctly spliced product,
densitometric analysis was performed using ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by
the National Institutes of Health, Bethesda, MD, USA).21 The
analysis was performed in duplicate, and values were
normalized for the size of the different fragments present in
each RT-PCR product mixture.
Penetrance Calculations
We assessed the penetrance of c.769-784C>T and
c.4253þ43G>A, when present in trans with a severe ABCA4
variant, by comparing the observed number of patients
carrying this combination of variants with the expected
number of patients.
The expected number of patients was calculated based on
ABCA4 allele frequency data of the general population, as
previously described.8,10 The cumulative frequency of severe
ABCA4 alleles was 0.00195, determined in our in-house whole-
exome sequencing dataset, containing data of 21,559 individ-
uals.10 We investigated the minor allele frequency (MAF) of the
intronic variants of interest in the non-Finnish European (nFE)
population in the Genome Aggregation Database (gno-
mAD),22,23 and the Dutch population in the Genome of The
Netherlands database (GoNL).24,25 The median age at diagnosis
in the study cohort of interest (i.e., c.769-784C>T or
c.4253þ43G>A carriers) served as a cut-off value to determine
the number of individuals in The Netherlands at risk for disease
due to both genotype and age.26
The observed number of patients carrying the intronic
variant of interest in The Netherlands could be extrapolated
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given the proportion of patients harboring the intronic variant
of interest at Radboud University Medical Center, the estimated




A total of 15 probands was included in this study, and in 13
probands, the trans configuration of the identified ABCA4
variants was confirmed (i.e., variants positioned on different
alleles; Fig. 1). In families S and R, DNA of relatives was not
available. Seven probands and one affected sibling harbored
c.[769-784C>T; 5603A>T] in trans with a severe ABCA4
variant. Eight probands and two affected siblings harbored
c.4253þ43G>A in trans with a severe ABCA4 variant. One
proband (M-II:1) also carried c.5603A>T on the same allele as
c.4253þ43G>A.
Clinical Characteristics
Detailed clinical characteristics of all subjects are displayed in
Supplementary Table S2. Patients presented with decreased
VA, central scotoma, and/or distorted vision, and one patient
was asymptomatic. Patients harboring c.[769-784C>T;
5603A>T] reported a median age at onset of 54.5 (range,
20–69) years. This did not significantly differ from the age of
onset among 33 patients carrying the noncomplex c.5603A>T
variant previously reported, of whom the median was 41
(range, 18–72) years8 (Mann-Whitney U: P ¼ 0.146, Supple-
mentary Fig. S1). Patients harboring c.4253þ43G>A had a
median age at onset of 52.0 (range, 20–68) years, while the
single patient who carried c.[4253þ43G>A; 5603A>T] had the
youngest age at onset of 18 years.
Patients harboring c.[769-784C>T; 5603A>T] mainly man-
ifested late-onset STGD1 characterized by pisciform yellow-
white flecks throughout the posterior pole and midperiphery
on fundoscopy, appearing hyperautofluorescent on FAF, and
sharply demarcated RPE atrophy in the macula on FAF,
corresponding to loss of the outer retinal layers from the
outer plexiform layer to the RPE on OCT, in a foveal-sparing
pattern (Fig. 2A).
One patient, sibling Q-II:2, had a discordant onset: Q-II:2
already reported initial symptoms at the age of 20 years.
Fundoscopy showed an abnormal foveal reflex with surround-
ing hypopigmentated lesions and yellow flecks at the age of 23,
with a VA of 20/63 in the right eye and 20/100 in the left eye
(Supplementary Fig. S2). Over the years, macular lesions of
RPE atrophy extended, surrounded by yellow-white flecks
throughout the posterior pole and midperiphery. During
triennial follow-up, VA gradually declined and reached 20/
200 in the left eye at the age of 26 years but not in the right eye
until the age of 39 years. In striking contrast, the brother, Q-
II:1, had an age at onset of 69 years and fundus features in
accordance with the characteristic findings of the group. The
VA first reached 20/200 in the right eye at the age of 75, while
FIGURE 1. Genetic data and age of onset. Pedigrees, genotype, and age at onset of all patients for whom segregation analysis has been performed.
Patient identifiers correspond with our previous genetic study in the genetically unexplained Stargardt cohort.14
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VA in the left eye still was 20/100 at the last visit, at age 78
years (Supplementary Fig. S2).
Patients harboring c.4253þ43G>A also mainly manifested
the characteristic late-onset STGD1 features. Six patients (H-I:2,
J-II:1, J-II:2, J-II:3, N-II:3, and R-II:3; age of onset 53, 68, 56, 61,
31, and 52 years, respectively) showed foveal sparing up to the
latest visit at age 63, 71, 75, 71, 42, and 68 years, respectively
(Fig. 2B). Yet, three patients (D-I:1, F-II:2, G-I:2) showed fewer
and smaller flecks, mostly confined to the macula, and did not
exhibit the typical foveal sparing atrophy. Instead, FAF of
patient D-I:1 and G-I:2 showed mottled decreased autofluores-
cence in the macula accompanied by one parafoveal, over the
years expanding, sharply demarcated atrophic lesion. Interest-
ingly, patient D-I:1 showed distinct intereye discordance in
FIGURE 2. Fundus imaging follow-up and visual acuity decline of three subjects who harbor different ABCA4 variants. The vertical lines represent
the moments that the FAF images of the right eyes were acquired. (A) Fundus photography (A1) and FAF of patient L-II:1 at the age of 63 (A2) and 69
years (A3). VA remained stable at 20/25 Snellen (0.8 decimal) (A4). This patient harbored c.[769-784C>T; 5603A>T] in trans with c.768G>T. (B)
Fundus photography (B1) and FAF of patient N-II:3 at the age of 38 (B2) and 42 years (B3), when VA was 20/25 (0.8) and 20/28 (0.7), respectively
(B4). This patient harbored c.4253þ43G>A in trans with c.4773þ1G>A. (C) Fundus photography (C1) and FAF of patient M-II:1 at the age of 21
(C2) and 24 years (C3), when VA was 20/50 (0.4) and 20/60 (0.3), respectively (C4). The patient harbored c.[4253þ43G>A; 5603A>T] in trans with
c.4539þ2001G>A.
FIGURE 3. Visual acuity survival. Kaplan-Meier survival plots for the time to reach severe visual impairment of patients carrying either of the two
intronic variants or the noncomplex c.5603A>T.
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fundoscopic features and the VA course (Supplementary Figs.
S2 and S3). At the age of 56, the right eye showed progressed
disease with a large macular lesion of definitely decreased
autofluorescence and RPE atrophy, whereas no RPE atrophy
was observed in the left eye during annual follow-up until the
age of 61.
Patient F-II:2 had a much younger age at onset of 20 years
and a rapid VA decline already at the age of 24 years. This
patient initially manifested central RPE alterations and peri-
foveal small yellow flecks. Over the years, flecks enlarged and
spread across the posterior pole, and beaten bronze macular
atrophy corresponding to mottled decreased autofluorescence
appeared (Supplementary Fig. S3).
Patient M-II:1, the single patient who harbored
c.4253þ43G>A in cis with c.5603A>T showed flecks mostly
confined to the macula, macular mottled decreased autofluo-
rescence, and macular loss of the outer nuclear layer and
ellipsoid zone at the age of 21, 3 years after the initial symptom
of VA loss (Fig. 2C). At the age of 24, VA in the right and left eye
had already declined to 20/66 and 20/100, respectively.
Results of ffERG were abnormal in only two of nine patients
in whom ffERG had been performed. Patients A-I:2 and H-I:2
had severely reduced responses under light-adapted conditions
and moderately reduced responses under dark-adapted condi-
tions at the age of 56 and 60 years, respectively.
Two patients had ocular comorbidity. Patient S-II:1 had mild
nonproliferative diabetic retinopathy and an amblyopic right
eye. Over a decade after onset of STGD1, patient D-I:1 suffered
from a central retinal vein occlusion in the right eye and a
hemiretinal vein occlusion in the left eye.
The VA courses of all eyes are depicted in Supplementary
Figure S2. Patients carrying c.[769-784C>T; 5603A>T] had a
median VA at the latest visit, at a median disease duration of 14
(range, 8–28) years, of 20/180 (decimal, 0.11; range, 0.05–1.0)
in the right eye and 20/125 (0.16; range, 0.05–0.63) in the left
eye. Patients carrying c.4253þ43G>A had a median VA at the
latest visit, at a median disease duration of 11 (range, 3–25)
years, of 20/125 (0.16; range, 0.03–1.0) in the right and 20/25
(0.8; range, 0.05–1.0) in the left eye.
Survival analysis of the time to severe visual impairment of
patients in this study and patients carrying the noncomplex
c.5603A>T in our STGD1 cohort showed comparable survival
times across groups, as depicted in Figure 3. Mean VA survival
times for patients carrying c.[769-784C>T; 5603A>T] versus
patients carrying the noncomplex c.5603A>T allele were 71
versus 69 years in the right eye, and 74 versus 71 years in the
left eye, respectively. Mean survival time for right eyes of
c.4253þ43G>A carriers was 66 years. All left eyes were
censored before reaching VA<20/200, at a median age of 63
(range, 25–71) years.
Splice Defect Due to c.769-784C>T in Patient-
Derived Photoreceptor Progenitor Cells
RT-PCR was performed in PPCs derived from subject A-I:2. In
the patient’s PPCs treated with cycloheximide, which blocks
nonsense-mediated decay of mRNA, gel analysis and Sanger
sequencing revealed a band of 327 nucleotides, corresponding
to the correct transcript, and another band of 489 nucleotides,
corresponding to a 162-nucleotides pseudo-exon insertion
(Supplementary Figs. S4 and S5). The pseudo-exon fragment
accounted for 15% of the total mRNA (Supplementary Table S3).
Reduced Penetrance of c.769-784C>T and
c.4253þ43G>A When Not Taking Into Account
Variants in Cis
The ‘observed’ number of STGD1 cases who harbor either
c.769-784C>T or c.4253þ43G>A in combination with a severe
ABCA4 variant in The Netherlands was extrapolated to be 29
and 46, respectively (Table).
TABLE. Penetrance Calculations for ABCA4 Variants c.769-784C>T and c.4253þ43G>A When in Trans With a Severe ABCA4 Variant, Not Taking
Cis Variants Into Account
c.769-784C>T c.4253þ43G>A
Observed number of patients
Proportion of STGD1 cases carrying severe variant and intronic variant of interest 0.0167 0.0267
Number of STGD1 cases with severe variant and intronic variant of interest in the NL* 29 46
Expected number of patients
Cumulative allele frequency of ABCA4 protein-truncating, canonical splice-site variants, and severe
noncanonical splice site variants in the NL† (p)
0.001953 0.001953
Allele frequencies of intronic variant of interest (q)
nFE gnomAD 0.004147 0.006030
GoNL 0.008016 0.005010
Frequencies of individuals with severe variant and intronic variant of interest (2pq)
Based on q nFE gnomAD 0.00001620 0.00002335
Based on q GoNL 0.00003131 0.00001957
Number of STGD1 cases with severe variant and the intronic variant of interest in the NL older than
the median age at diagnosis‡
Based on q nFE gnomAD 72 128
Based on q GoNL 139 106
Penetrance
Penetrance of a severe variant with the intronic variant (observed/expected number of patients)
Based on q nFE gnomAD 39.6% 35.8%
Based on q GoNL 20.5% 43.1%
NL, population of The Netherlands
* Conservatively assuming STGD1 prevalence in The Netherlands to be 1:10,000. Total Dutch population: 17,150,000.
† Based on in vitro splice assays of noncanonical splice-site variants.35
‡ Median age at diagnosis in the c.769-784C>T cohort and the c.4253þ43G>A cohort was 59 and 55 years, respectively.
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The ‘expected’ number of patients carrying c.769-784C>T
in combination with a severe variant was 72, based on the nFE
MAF of c.769-784C>T of 0.00415. Based on the 2-fold higher
Dutch MAF of c.769-784C>T (0.00802), 139 individuals were
expected to be at risk for disease due to the ABCA4 variants
they harbor and their age (higher than median age at diagnosis
in patient cohort).
For c.4253þ43G>A, the ‘expected’ number of patients was
128, based on a nFE MAF of c.4253þ43G>A of 0.00603. Based
on a slightly different Dutch MAF of c.4253þ43G>A of
0.00501, 106 individuals were expected to be at risk.
For c.769-784C>T and c.4253þ43G>A in trans with a
severe ABCA4 variant, comparison of the expected numbers of
patients with the observed number of patients in The
Netherlands resulted in an estimated penetrance of 20.5%
(Dutch MAF) to 39.6% (nFE MAF) and 35.8% (nFE MAF) to
43.1% (Dutch MAF), respectively.
DISCUSSION
Following the common c.5603A>T coding variant,7,8 two
recently discovered frequent deep-intronic ABCA4 variants
could further explain the missing heritability in late-onset
STGD1.14,15 The majority of the subjects in this study
manifested late-onset STGD1 (72%) characterized by pisciform
flecks throughout the posterior pole and midperiphery, and
macular sharply demarcated RPE atrophy—if present at all—in
a foveal-sparing pattern. No significant differences with respect
to phenotypic features and VA course were observed between
the c.769-784C>T and the c.4253þ43G>A cohort.
The identification of the second disease-causing ABCA4
allele in an increasing number of patients with late-onset
STGD1 undeniably anchors the described phenotype in the
spectrum of ABCA4 disease. Still, patients are initially
misdiagnosed with AMD on a regular basis. Important
phenotypic differential diagnostic findings in late-onset STGD1
are the flecks, which, compared with drusen, are more
irregularly shaped, often more intensely hyperautofluorescent
on FAF images, often but not always more diffusely spread
across the posterior pole and midperiphery28 and correspond
to hyperreflective depositions traversing photoreceptor-attrib-
utable bands on OCT.29 Also, in contrast to AMD, STGD1 is
only very rarely complicated by a neovascularization.30,31 The
correct clinical diagnosis and the identification of underlying
genetic variants have become paramount with emerging
therapies for both STGD1 and geographic atrophy in AMD,
not only for proper patient selection for trials, but also for the
identification of therapeutic targets. In fact, both c.769-
784C>T and c.4253þ43G>A ABCA4 variants were already
shown to be targets for partial splice correction by antisense
oligonucleotides.14
Although most subjects exhibited characteristic late-onset
STGD1 features, we observed notable clinical variability among
subjects carrying the same combination of an intronic and a
severe ABCA4 variant, even among siblings (family Q) and
within subjects (D-I:1). Both the c.[769-784C>T; 5603A>T]
and c.4253þ43G>A cohort had a large range in age of onset,
and VA courses varied widely. No comorbidities nor other
factors were perceived that might explain the clinical
variability. These results suggest that factors outside ABCA4
may modify the disease course. A few studies indicated that the
activation of the complement cascade could play a role in the
pathogenesis of STGD1.32,33 Parallel to the complement
cascade, other overlapping disease-modifying factors might
act in late-onset STGD1 and AMD.
RNA analysis in patient-derived PPCs showed that c.769-
784C>T results in a pseudo-exon insertion in 15% of total
mRNA, compared with 8.6% in HEK293T cells assessed
previously.14 As the other allele of this patient harbored a
missense variant (p.Phe608Ile), which is not expected to affect
mRNA stability, the 15% defective total mRNA is considered to
result from a 30% defective mRNA transcript from the c.769-
784C>T allele alone, assuming that the missense allele in trans
is equally expressed. The RNA analysis in PPCs corroborated a
mild effect of c.769-784C>T on splicing. A similar observation
was made for variant c.4539þ2028C>T, which led to a 345-nt
pseudo-exon insertion in patient-derived PPCs in 15% of total
mRNA and approximately 30% of mRNA derived from the allele
carrying c.4539þ2028C>T.20 In contrast, no pseudo-exon
insertion was found in fibroblasts of the same patient. These
results strongly suggest that retina-specific splice factors play a
role in the defects observed for both c.769-784C>T and
c.4539þ2028C>T.
Despite the enrichment of the complex c.[769-784C>T;
5603A>T] allele among patients versus controls14 and our
splice assays that indicate that variant c.769-784C>T has an
additive pathogenic effect, significant clinical differences
between patients who harbor c.[769-784C>T; 5603A>T]
versus patients only harboring c.5603A>T were not observed.
In the genetic study, the age of onset among patients carrying
c.[769-784C>T; 5603A>T] was higher than the age of onset of
patients carrying the single c.5603A>T variant, but the other
cohort was smaller and included patients from abroad.14
Variant c.4253þ43G>A was found in cis with c.5603A>T in
only one patient. Interestingly, this patient had a strikingly early
age of onset (18 years), discordant phenotype in fundo and a
relatively fast VA decline. These results suggest that variant
c.5603A>T and other, yet unidentified, cis variants might
influence the expression, and possibly the penetrance, of the
ABCA4 allele.
We calculated the penetrance of c.769-784C>T and
c.4253þ43G>A, when present in trans with a severe variant,
and found that, respectively, 20.5% to 39.6% and 35.8% to
43.1% of the individuals carrying these ABCA4 variants actually
manifest STGD1. Other ABCA4 variants on the same allele
might well influence the penetrance. In fact, in this study
cohort, variant c.769-784C>T was consistently found in cis
with c.5603A>T, the mild variant for which we previously
calculated an extremely low penetrance (~5%), and for which
we consequently argued that yet unidentified factors explain
its penetrance in patients.8,10 It is possible that c.5603A>T acts
as a modifier that results in full penetrance of the complex
c.[769-784C>T; 5603A>T] allele. As expected, we recently
identified variant c.769-784C>T without c.5603A>T in two
late-onset STGD1 cases in a large follow-up study (Khan M,
Cremers FPM, unpublished observations, 2019). Further
studies are needed to corroborate current findings and provide
undeniable evidence of the pathogenicity of the c.769-784C>T
variant.
This study has a few limitations, mainly due to the
complexity of penetrance calculations discussed previously.8,10
Population differences in the prevalence of the variants of
interest and severe variants influence the calculated pene-
trance. To minimize the risk of this sampling bias, we used and
compared allele frequencies of the European and the Dutch
population. Missense variants that might have a severe effect
on ABCA4 protein function were not included in the
calculation of severe ABCA4 variant frequency, which has
most likely resulted in overestimation of the calculated
penetrance.34 Second, age of onset was defined as the age at
which the patient first experienced visual complaints. Alter-
natively, if complaints were absent or not reported (in only 2
subjects), we used age at which decrease in VA was first
documented or the age at which macular abnormalities were
first diagnosed. To a larger degree, age of onset might be
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influenced by recall bias and other patient-specific factors,
such as daily activities, comorbidities, and location of lesions.
In conclusion, this study showed that intronic ABCA4
variants resulting in a mild splice defect, in addition to the
coding c.5603A>T variant, could genetically explain a large
proportion of the late-onset STGD1 cases, which aids in the
differential diagnosis of late-onset STGD1 and AMD. At the
same time, these mild variants were associated with a notable
clinical variability, which needs to be considered in the design
of upcoming clinical trials. The results of the present study and
our previous studies on c.5603A>T,8,10 indicating that cis
variants, such as c.5603A>T, as well as factors outside ABCA4
could modify the disease course, should be considered in
family counseling and warrant further studies on STGD1
modifiers.
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